User login
Key clinical point: Upadacitinib is effective and safe for the treatment of patients with difficult-to-treat moderate-to-severe atopic dermatitis (AD).
Major finding: At week 16, the percentages of patients achieving the Eczema Area and Severity Index (EASI) 50, EASI 75, EASI 90, and EASI 100 were 94.29%, 91.43%, 74.29%, and 60.0%, respectively; 91.43% of patients achieved a ≥4-point decrease in itch-numerical rating scale score. No severe adverse events were reported.
Study details: This single-center retrospective real-life study included 38 patients aged ≥12 years with moderate-to-severe AD and inadequate response, intolerance, or contraindications to cyclosporine or dupilumab who had received upadacitinib (15/30 mg daily) for ≥8 weeks; 35 patients received the treatment for 16 weeks.
Disclosures: This study was supported by grants from Fondazione Roma, Italian Ministry of Health (Rome, Italy), “Ricerca Finalizzata” project. Some authors reported ties with various organizations.
Source: Gargiulo L et al. Real-life effectiveness and safety of upadacitinib in adults and adolescents with moderate-to-severe atopic dermatitis: A single-center 16-week study. Dermatol Ther (Heidelb). 2023 (Jan 9). Doi: 10.1007/s13555-022-00882-z
Key clinical point: Upadacitinib is effective and safe for the treatment of patients with difficult-to-treat moderate-to-severe atopic dermatitis (AD).
Major finding: At week 16, the percentages of patients achieving the Eczema Area and Severity Index (EASI) 50, EASI 75, EASI 90, and EASI 100 were 94.29%, 91.43%, 74.29%, and 60.0%, respectively; 91.43% of patients achieved a ≥4-point decrease in itch-numerical rating scale score. No severe adverse events were reported.
Study details: This single-center retrospective real-life study included 38 patients aged ≥12 years with moderate-to-severe AD and inadequate response, intolerance, or contraindications to cyclosporine or dupilumab who had received upadacitinib (15/30 mg daily) for ≥8 weeks; 35 patients received the treatment for 16 weeks.
Disclosures: This study was supported by grants from Fondazione Roma, Italian Ministry of Health (Rome, Italy), “Ricerca Finalizzata” project. Some authors reported ties with various organizations.
Source: Gargiulo L et al. Real-life effectiveness and safety of upadacitinib in adults and adolescents with moderate-to-severe atopic dermatitis: A single-center 16-week study. Dermatol Ther (Heidelb). 2023 (Jan 9). Doi: 10.1007/s13555-022-00882-z
Key clinical point: Upadacitinib is effective and safe for the treatment of patients with difficult-to-treat moderate-to-severe atopic dermatitis (AD).
Major finding: At week 16, the percentages of patients achieving the Eczema Area and Severity Index (EASI) 50, EASI 75, EASI 90, and EASI 100 were 94.29%, 91.43%, 74.29%, and 60.0%, respectively; 91.43% of patients achieved a ≥4-point decrease in itch-numerical rating scale score. No severe adverse events were reported.
Study details: This single-center retrospective real-life study included 38 patients aged ≥12 years with moderate-to-severe AD and inadequate response, intolerance, or contraindications to cyclosporine or dupilumab who had received upadacitinib (15/30 mg daily) for ≥8 weeks; 35 patients received the treatment for 16 weeks.
Disclosures: This study was supported by grants from Fondazione Roma, Italian Ministry of Health (Rome, Italy), “Ricerca Finalizzata” project. Some authors reported ties with various organizations.
Source: Gargiulo L et al. Real-life effectiveness and safety of upadacitinib in adults and adolescents with moderate-to-severe atopic dermatitis: A single-center 16-week study. Dermatol Ther (Heidelb). 2023 (Jan 9). Doi: 10.1007/s13555-022-00882-z